HIF-1α and RKIP: a computational approach for pancreatic cancer therapy

被引:0
|
作者
Gowru Srivani
Santosh Kumar Behera
Begum Dariya
Gayathri Chalikonda
Afroz Alam
Ganji Purnachandra Nagaraju
机构
[1] Banasthali University,Department of Bioscience and Biotechnology
[2] ICMR-Regional Medical Research Centre,Biomedical Informatics Centre
[3] Emory University,Department of Hematology and Medical Oncology, Winship Cancer Institute
来源
Molecular and Cellular Biochemistry | 2020年 / 472卷
关键词
Cluster; HADDOCK; HIF-1α; Interaction; Pancreatic cancer; RKIP;
D O I
暂无
中图分类号
学科分类号
摘要
Protein–protein interactions (PPIs) are important biochemical processes that represent a major challenge in modern biology. Current approaches, which include high-throughput screening and computer aided ligand design, have limitations regarding the identification of hit matter. This current investigation focuses on computational study for protein–protein docking of hypoxia inducible factor-1α (HIF-1α), a tumor inducible factor, and Raf-1 kinase inhibitory protein (RKIP), a tumor metastasis suppressor. These are individually crystallized structures of interacting proteins, which interact to generate a conformational space. HIF activity in pancreatic tumors is determined by hypoxia and HIF-1α subunit availability. RKIP can be used as a prognostic indicator in a number of tumors. The interaction of RKIP with HIF-1α protects against pancreatic cancer (PC) metastasis by inhibiting its hypoxia function. We have explored the binding affinity between both the proteins with the HADDOCK (high ambiguity driven protein–protein docking) server, which determined that 158 structures in 11 clusters represent 79.0% of water-refined models. Of the best 10 clusters, the structures of cluster 2 were found to be better, as they had the lowest Z-score. Further supporting HIF-1α-RKIP interaction, pulldown assay has shown dissociation of RKIP from HIF-1α after CoCl2 treatment in both PC cell lines.
引用
收藏
页码:95 / 103
页数:8
相关论文
共 50 条
  • [1] HIF-1α and RKIP: a computational approach for pancreatic cancer therapy
    Srivani, Gowru
    Behera, Santosh Kumar
    Dariya, Begum
    Chalikonda, Gayathri
    Alam, Afroz
    Nagaraju, Ganji Purnachandra
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2020, 472 (1-2) : 95 - 103
  • [2] Expression and significance of HIF-1α and HIF-2α in pancreatic cancer
    Min Wang
    Mei-yuan Chen
    Xing-jun Guo
    Jian-xin Jiang
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2015, 35 : 874 - 879
  • [3] Expression and Significance of HIF-1α and HIF-2α in Pancreatic Cancer
    王敏
    陈美源
    郭兴军
    江建新
    Current Medical Science, 2015, (06) : 874 - 879
  • [4] Expression and significance of HIF-1α and HIF-2α in pancreatic cancer
    Wang, Min
    Chen, Mei-yuan
    Guo, Xing-jun
    Jiang, Jian-xin
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2015, 35 (06) : 874 - 879
  • [5] Implications of HIF-1α in the tumorigenesis and progression of pancreatic cancer
    Jin, Xiao
    Dai, Lu
    Ma, Yilan
    Wang, Jiayan
    Liu, Zheng
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [6] Implications of HIF-1α in the tumorigenesis and progression of pancreatic cancer
    Xiao Jin
    Lu Dai
    Yilan Ma
    Jiayan Wang
    Zheng Liu
    Cancer Cell International, 20
  • [7] Prognostic significance of HIF-1α overexpression in human pancreatic cancer
    Shibaji, T
    Nagao, M
    Ikeda, N
    Kanehiro, H
    Hisanaga, M
    Ko, S
    Fukumoto, A
    Nakajima, Y
    ANTICANCER RESEARCH, 2003, 23 (6C) : 4721 - 4727
  • [8] Resveratrol binds and inhibits transcription factor HIF-1α in pancreatic cancer
    Srivani, Gowru
    Behera, Santosh Kumar
    Dariya, Begum
    Aliya, Sheik
    Alam, Afroz
    Nagaraju, Ganji Purnachandra
    EXPERIMENTAL CELL RESEARCH, 2020, 394 (01)
  • [9] miR-212 regulated by HIF-1 promotes the progression of pancreatic cancer
    Yue, Hui
    Liu, Lin
    Song, Zhenguo
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (03) : 2359 - 2365
  • [10] HIF-1α links β-adrenoceptor agonists and pancreatic cancer cells under normoxic condition
    Hu, Heng-tong
    Ma, Qing-yong
    Zhang, Dong
    Shen, Su-gang
    Han, Liang
    Ma, Ya-dong
    Li, Ruo-fei
    Xie, Ke-ping
    ACTA PHARMACOLOGICA SINICA, 2010, 31 (01) : 102 - 110